Cystic Fibrosis News Digest — Issue 03

Fatih Ercan, Sevgi Pekcan, Semih Erden, et al.

Summary: Researchers in Turkey studied a group of teenagers aged 14–18 with cystic fibrosis and compared them with healthy teenagers of the same age. They measured something called alexithymia — a reduced ability to recognise and put words to one's own feelings. Using a standard questionnaire called the Toronto Alexithymia Scale, teenagers with CF scored significantly higher than healthy peers, meaning they had more difficulty with emotional awareness. The study also found that teenagers with worse lung function tended to score higher on this scale, though whether one causes the other is not known.

Why it matters: When people struggle to identify or describe their own emotions, it can make it harder to communicate with doctors, stick to demanding treatment routines, and benefit from psychological support. If difficulty with emotional awareness is genuinely more common in teenagers with CF — especially those whose lung health is declining — care teams may need to pay closer attention to this, not just to physical symptoms. The study raises a practical question: are CF clinics doing enough to check for emotional processing difficulties in their teenage patients?

What to keep in mind: This study looked at teenagers at one point in time, so it cannot tell us whether trouble recognising emotions leads to worse lung health, whether living with serious illness makes emotional processing harder, or whether both reflect something else entirely. We also do not know how many teenagers were included, which matters because small studies in rare diseases can produce uncertain results. Teenagers with other serious conditions were not included as a comparison group, so it is unclear whether this pattern is specific to CF or common to chronic illness more broadly. The finding is interesting and worth investigating further, but it is best understood as an early signal rather than a firm conclusion.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42631608/

---

MacKenzie L Wyatt, Karen S Raraigh, Anna V Faino, et al.

Summary: When newborn screening detects a possible CF-related gene change that does not clearly cause CF, the baby is given a designation called CRMS/CFSPID (CF screen positive, inconclusive diagnosis). Some of these babies will eventually develop CF; others will not. This study pooled data from 25 published reports covering 606 children to ask whether the specific genetic variant found changes the odds of a child later being diagnosed with CF. Among children carrying one uncertain variant paired with one CF-causing variant, 28% eventually received a full CF diagnosis — but the risk varied greatly depending on which uncertain variant was present. Some variants were associated with conversion rates of 50% or higher; others carried much lower risk.

Why it matters: Families of babies with an inconclusive newborn screening result often face months or years of uncertainty and repeated testing. Knowing that the specific genetic variant matters — and that some carry much higher risk than others — gives doctors and genetic counsellors a more useful basis for having those conversations. It also has implications for which gene variants are included in newborn screening programmes, since that choice directly affects how many families face this kind of uncertainty.

What to keep in mind: Although 606 children sounds like a reasonable number, once the data are broken down by individual variant, most of the risk estimates are based on very few children. This makes the specific numbers uncertain — they could shift considerably as more cases are reported. The 25 studies pooled here were conducted in different countries, at different times, and used slightly different rules for what counts as a CF diagnosis, which adds further uncertainty. Studies that followed children for shorter periods will have missed some cases that only became apparent later, meaning the true conversion rates may be higher than reported. These limitations do not undermine the core message — that risk varies meaningfully by variant — but they do mean the precise percentages should be treated as rough guides rather than definitive figures.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42629235/

---

Marcus Svedberg, Christina Krantz, Henrik Imberg

Summary: Children with CF typically perform airway clearance exercises — physical techniques and inhaled salt-water mist (hypertonic saline) — twice a day to keep their airways clear of mucus. This Swedish study followed 46 children aged 6–17, all taking the triple combination drug ETI, who reduced their airway clearance routine from twice to once daily. Over 12 months, lung function remained essentially stable. A sensitive test of how evenly air moves through the lungs showed a small, statistically non-significant improvement. Antibiotic use fell by 39%, and respiratory symptoms and the bacteria found in the airways stayed stable.

Why it matters: Airway clearance routines are time-consuming and demanding, particularly for children and families already managing a complex treatment schedule. The question of whether ETI — which substantially improves how the CF protein works — makes some of this routine burden unnecessary is an important and practical one. This study offers prospective, structured evidence that cutting the routine in half did not appear to harm lung health over one year. The drop in antibiotic use is also notable, though it requires careful interpretation.

What to keep in mind: The most important limitation is that this study had no comparison group — there were no children who continued twice-daily treatment alongside those who reduced it. Without that comparison, it is impossible to be certain whether stability reflected the safety of the reduction or simply the natural course of ETI-treated children, who might have remained stable regardless. Forty-six children is also a modest number, and the range of plausible outcomes in the lung test data includes the possibility of a meaningful decline that the study was too small to detect with confidence. One year may not be long enough to capture slow, gradual changes in lung structure that accumulate quietly over time. The drop in antibiotic use is interesting but could partly reflect a change in clinical behaviour — clinicians or families being less inclined to treat minor symptoms — rather than genuinely fewer infections. These results are a useful early signal, but a larger, longer, and ideally randomised study is needed before reducing airway clearance routines becomes standard practice.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42632792/

---

Vincenzo G Menditto, Giovanni Pomponio, Nicole Caporelli, et al.

Summary: Meconium ileus — a bowel blockage caused by abnormally thick intestinal contents — affects roughly 15–20% of newborns with CF and often requires major surgery. Researchers reviewed 18 published reports to ask whether giving CFTR modulator drugs (primarily ETI) to pregnant women — either women who themselves have CF or women who carry one CF gene — might prevent or reduce this complication. Among 42 fetuses that had been identified before birth as having meconium ileus and whose mothers received modulator therapy, only 12% required surgery. This was compared with a historical group — babies born in earlier years without this treatment — where surgical rates were substantially higher. None of nine fetuses without visible meconium ileus who were exposed to modulator therapy developed the condition.

Why it matters: As more women with CF reach reproductive age and as prenatal genetic testing becomes more common, the question of whether modulator therapy during pregnancy can protect the baby is increasingly relevant. Surgery for meconium ileus in a newborn carries real risks, and avoiding it would matter greatly to affected families. The biological idea is plausible: the drug passes through the placenta and could help the baby's gut function more normally before birth.

What to keep in mind: The evidence here is built almost entirely from individual case reports and very small series — the kind of early-stage information used to generate hypotheses, not to confirm them. Pooling 18 such reports is a rigorous analytical approach, but it cannot make weak underlying evidence strong. The comparison with historical cases is particularly uncertain: babies born in earlier years were tested, diagnosed, and cared for differently, and families whose pregnancies were managed with modulator therapy in recent years likely received closer monitoring and earlier intervention regardless of the drug. With only 42 fetuses in the treated group, the range of plausible outcomes is wide. Some of the statistical analyses involve such small numbers that the results are highly imprecise — wide enough to be compatible with very different realities. This paper is the best available summary of limited early evidence, and the signal is worth taking seriously. It does not, however, support routine use of modulator drugs in carrier mothers specifically to prevent fetal bowel problems outside of carefully designed studies. The authors themselves say the same.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42632793/

---

Christina L Duncan, Megan von Isenburg, Angela Green, et al.

Summary: This study looked at mental and emotional health in 118 young people with CF, aged 7–17, all taking ETI, and their caregivers, across 11 US CF centres. Roughly one in four to one in three caregivers and young people showed clinically meaningful signs of depression or anxiety. Nearly a third of the young people had notable sleep problems. Importantly, caregivers who reported worse mental health tended to have children who also showed more mental health symptoms — the two were meaningfully connected.

Why it matters: ETI has dramatically improved physical health for many people with CF, but this study shows that emotional and psychological burdens have not simply disappeared alongside the lung symptoms. The connection between caregiver mental health and child mental health is especially significant: it suggests that focusing only on the child and ignoring the parent or carer may leave an important source of distress unaddressed. For CF care teams, this is a reminder that mental health screening and support remain relevant — and that involving the whole family, not just the patient, deserves serious attention.

What to keep in mind: This study captured a snapshot at one point in time and cannot tell us whether these mental health rates are better, worse, or the same as before ETI became available. Without a comparison group of young people not on ETI, or data from before the modulator era, it is difficult to know how much CF specifically contributes versus broader trends — youth mental health difficulties have increased across the general population in recent years, particularly since the pandemic. The 118 participants, spread across 11 centres, give fairly wide margins of uncertainty around the specific percentages reported. The fact that many of these centres are likely large academic programmes also means the findings may not reflect experience at smaller or less specialised clinics. The connection between caregiver and child mental health is consistent with a large body of research in paediatric chronic illness generally. These findings reinforce existing clinical guidance to maintain mental health services for CF families in the ETI era rather than scale them back.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42621765/

---

Tuğba Nur Gür, Zehra Buşra Azizoğlu, Yesim Haliloğlu, et al.

Summary: The immune system uses chemical signals called cytokines to coordinate responses to infection and injury. This small study measured several cytokines in the blood of 20 children with stable CF, 8 children with CF during a lung flare-up, and 20 healthy children. In stable CF, cells that produce a cytokine called IL-22 were elevated, while circulating levels of another cytokine, IL-17A — often associated with the kind of inflammation seen in CF airways — were lower than in healthy children. The pattern during a flare-up differed from the stable state, though the small numbers make firm conclusions difficult.

Why it matters: Understanding how the immune system behaves in CF — and whether that behaviour changes with disease activity — could eventually help researchers develop better ways to monitor disease or identify new treatment targets. The finding that systemic (whole-body) immune signals differ from what is seen locally in the airways is a useful reminder that blood tests may not fully capture what is happening in the lungs.

What to keep in mind: This is a very small study — 20 children in each main group, and only 8 during a flare-up — which makes all of the findings uncertain. The study looked at children at one point in time, so it cannot tell us whether the immune patterns observed cause CF lung problems, result from them, or simply coexist. A significant gap is that it is unclear which children were taking ETI or other CFTR modulator drugs, which are known to alter immune responses. If some children were on modulators and others were not, this could explain some of the differences seen, independently of disease activity. The finding of lower IL-17A in stable CF — when this cytokine is often thought to drive CF airway inflammation — is intriguing but not yet explained. The authors appropriately describe this as early, hypothesis-generating work that needs to be confirmed in larger studies over time.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42606614/

---